{"id":"https://genegraph.clinicalgenome.org/r/af92c3c0-0482-4f28-96e3-9ae83a725a03v1.1","type":"EvidenceStrengthAssertion","dc:description":["*STAT3* was first reported in relation to autosomal dominant hyper IgE syndrome (HIES) in 2007 (PMID: 17881745). *STAT3* loss-of-function (LOF) variants are associated with elevated serum IgE, eczema, and recurrent skin and respiratory tract infections. Patients also have other clinical manifestations that display variable expressivity, including eosinophilia, chronic mucocutaneous candidiasis, systemic allergic manifestations, and extra-hematopoietic features. Over 143 heterozygous variants of *STAT3* had been reported in patients with HIES (PMID: 34137790). These 143 variants include 114 missense mutations, 21 in-frame indels, and 8 nonsense or frameshift indels. Deep intronic variants have also been identified in *STAT3* and have been shown to result in dominant negative (DN) effect on *STAT3* function (PMID: 31346092). Most of the mutations cluster to the DNA binding domain and SH2 domain. For this curation, 14 variants in 14 probands in 4 publications are included (PMID: 17676033, 18602572, 22751495, 31346092). The maximum score for genetic evidence (12 pts.) was reached in this curation and no further variants are included.\n\nThis gene-disease association is also supported by functional assays, animal models and rescue experiments. After receptor-ligand binding, STAT3 is phosphorylated by receptor associated Janus kinases (JAK), causing formation of STAT homo- or heterodimers, followed by translocation into the nucleus to act as a transcription factor. Mechanistically, STAT3 mutated HIES is driven by dominant negative (DN) variants resulting in reduced STAT3 functionality in cells involved with immunity, osteogenesis, and other biological processes. Using a luciferase based STAT3 transcriptional activity assay, transfection of *STAT3* LOF variants into STAT3 sufficient cells demonstrated almost all variants cause a dominant negative (DN) reduction in STAT3 activity (PMID: 34137790). No cases of *STAT3* LOF variants leading to haploinsufficiency were identified using this experimental approach. HIES patients with *STAT3* LOF variants demonstrate variable levels of pSTAT3 compared to WT, but reproducibly show B cell dysfunction, decreased T helper 17 (Th17) CD4 T cell differentiation and elevated frequencies of IgE+ B cells (PMID: 33045280, 18602572). Two distinct mouse models were curated to supported *STAT3* LOF variants as a mechanism of HIES. These two models demonstrated increased IgE production, increased susceptibility to infection, and decreased TH17 CD4 T cell responses, replicating patient phenotypes (PMID: 31026806, 24632714). Rescue experiments using CRISPR base editing demonstrated increased pSTAT3 levels, STAT3 activity and increased STAT3-dependent cytokine signaling following reversion (PMID: 33876960). In a patient with HIES, HSCT resulted in normalization of TH17 CD4 T cell number, serum IgE levels, STAT3-dependent cytokine signaling and improvement in other HIES associated clinical features (PMID:25962528).\n\n\nIn summary, *STAT3* is definitively associated with hyper-IgE syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen SCID/CID GCEP on the meeting date, December 16, 2021 (SOP Version 8).","STAT3 was first reported in relation to early-onset multisystem autoimmune disease in 2014 (PMID: 25038750). STAT3 gain-of-function (GOF) variants are associated with lymphoproliferation, autoimmunity and hypogammaglobulinemia. There is a wide array of clinical symptoms observed and is hypothesized to be due to differences in the variantâ€™s location in functional domains of STAT3 (PMID: 31770611). Some STAT3 GOF mutations exhibit incomplete penetrance in the population, suggesting that STAT3 GOF mutations alone are not enough to cause disease in some cases. Over 49 variants have been reported in the literature (PMID: 34366294). For this curation, 10 variants in 10 probands in 3 publications (PMIDs: 25359994, 25349174, 25038750) are included. The maximum score for genetic evidence (12 pts.) was reached in this curation and no further variants are included.  \n\nThis gene-disease association is also supported by expression studies, functional assays, and animal models. STAT3 is important in cytokine and growth factor signaling. STAT3 is phosphorylated by receptor associated Janus kinases (JAK), causing formation of STAT homo- or heterodimers, followed by translocation into the nucleus to act as a transcription factor. STAT3 is widely expressed and is important for many processes in immunity, cell growth and apoptosis. The exact mechanism leading to STAT3 GOF disease is unknown due to the wide array of functions STAT3 can perform. However, there is evidence STAT3 GOF variants impact immune cell function, leading to autoimmunity. STAT3 GOF variants lead to higher levels of functional pSTAT3 in patient cells (PMID: 25359994), and lead to increases in negative regulators of cytokine signaling, suggesting over-activity of immune cells (PMID: 25359994). Supporting this finding, groups have shown increased differentiation of T helper 17 cells (TH17) in STAT3 GOF patients (PMID: 26343524), a cell type that is implicated in mediating many autoimmune diseases. Lastly, the generation of a mouse model substituting a STAT3 patient variant led to increased incidence of diabetes mediated by CD8 T cells (PMID: 34115115), as identified in a subset of STAT3 GOF patients. Altogether, published evidence suggests the STAT3 GOF variants are leading to immune cells with increased reactivity and likelihood to cause autoimmunity. However, more mechanistic studies are needed to fully understand the range of clinical symptoms seen in patients.\n\nOf note, STAT3 GOF mutations have been identified in cases of large granulocytic leukemia (LGL) (PMID: 23207521, 22591296), and likely represent a pathogenic driver of this somatic process. There have been reports of individuals with germline STAT3 GOF developing LGL, though the prevalence of LGL cases caused by germline STAT3 GOF variants is unknown. Future review of this curation will need to assess the relationship between LGL and germline STAT3 GOF variants as more research is performed.\n\nIn summary, STAT3 is definitively associated with early-onset multisystem autoimmune disease. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen SCID/CID GCEP on December 16, 2021 (SOP Version 8).\n"],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/af92c3c0-0482-4f28-96e3-9ae83a725a03","GCISnapshot":"https://genegraph.clinicalgenome.org/r/beb3aa5b-240e-45d7-969a-9de3e5564457","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/beb3aa5b-240e-45d7-969a-9de3e5564457_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10081","date":"2025-06-16T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/beb3aa5b-240e-45d7-969a-9de3e5564457_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10081","date":"2025-06-24T14:32:06.318Z","role":"Publisher"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/beb3aa5b-240e-45d7-969a-9de3e5564457_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9f27c9ff-4625-4cf3-80b2-b409b3668cf8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9f27c9ff-4625-4cf3-80b2-b409b3668cf8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22751495","allele":{"id":"https://genegraph.clinicalgenome.org/r/1dbbbbaf-3a1d-4bab-8d94-dbb103162034","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.2123C>A (p.Thr708Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399580219"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/9f27c9ff-4625-4cf3-80b2-b409b3668cf8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"patient B cells were transformed with EBV and treated with IL-6, IL-10, IL-21, or IFNa. Cells were assessed for pStat3 (pY705) by flow cytometry, stat3 nuclear translocation by EMSA ELISA, and mRNA levels of stat3-responsive gene (SOCS3) via RT-PCR following cytokine treatment. patient cells showed decreased phosphorylation, nuclear translocation, and induction of SOCS3 transcritption following IL-6 treatment (and to a lesser extent following treatment with other cytokines) compared to controls. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/05fe5dfe-810e-4231-a534-77932d407e34","type":"EvidenceLine","dc:description":"This variant was scored 1.5 points as there were strong functional studies demonstrating STAT3 LOF when the variant was present.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/05fe5dfe-810e-4231-a534-77932d407e34_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17676033","allele":{"id":"https://genegraph.clinicalgenome.org/r/27487155-5b3a-411c-b7aa-af5ee26cf851","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1166C>T (p.Thr389Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA264235"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/05fe5dfe-810e-4231-a534-77932d407e34_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Showed that IL-6 and IL-10 is reduced in patient cells. Using EBV transformed cells showed that STAT3 DNA binding activity of patient samples was reduced compared to controls. Lastly, HeLa cells were transduced with WT STAT3 or patient variants and then silenced WT STAT3 using siRNA, finding this variant reduced STAT3 functionality.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/48222492-3008-4ea7-b0f0-99b3bad75b6b","type":"EvidenceLine","dc:description":"This variant was scored 1.5 points as there were strong functional studies demonstrating STAT3 LOF when the variant was present.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/48222492-3008-4ea7-b0f0-99b3bad75b6b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17676033","allele":{"id":"https://genegraph.clinicalgenome.org/r/7c5c5b59-4304-4db4-bf4d-ebb3975dc9bb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1384GTG[1] (p.Val463del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341501"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/48222492-3008-4ea7-b0f0-99b3bad75b6b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Showed that IL-6 and IL-10 is reduced in patient cells. Using EBV transformed cells showed that STAT3 DNA binding activity of patient samples was reduced compared to controls. Lastly, HeLa cells were transduced with WT STAT3 or patient variants and then silenced WT STAT3 using siRNA, finding this variant reduced STAT3 functionality.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/594b274d-039a-45e2-97d1-a70681002814","type":"EvidenceLine","dc:description":"This variant was scored 1.5 points as there were strong functional studies demonstrating STAT3 LOF when the variant was present.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/594b274d-039a-45e2-97d1-a70681002814_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17676033","allele":{"id":"https://genegraph.clinicalgenome.org/r/82e1d7b4-f10d-4f41-92fd-c09a820fa431","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1144C>T (p.Arg382Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341504"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/594b274d-039a-45e2-97d1-a70681002814_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Showed that IL-6 and IL-10 is reduced in patient cells. Using EBV transformed cells showed that STAT3 DNA binding activity of patient samples was reduced compared to controls. Lastly, HeLa cells were transduced with WT STAT3 or patient variants and then silenced WT STAT3 using siRNA, finding this variant reduced STAT3 functionality.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/86399d05-f677-40a7-ba6b-f17f0b0ec303","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/86399d05-f677-40a7-ba6b-f17f0b0ec303_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22751495","allele":{"id":"https://genegraph.clinicalgenome.org/r/85e47d9f-789b-4b5a-9939-dd9a0785d30f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1234A>T (p.Thr412Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399588516"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/86399d05-f677-40a7-ba6b-f17f0b0ec303_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"patient B cells were transformed with EBV and treated with IL-6, IL-10, IL-21, or IFNa. Cells were assessed for pStat3 (pY705) by flow cytometry, stat3 nuclear translocation by EMSA ELISA, and mRNA levels of stat3-responsive gene (SOCS3) via RT-PCR following cytokine treatment. patient cells showed decreased phosphorylation, nuclear translocation, and induction of SOCS3 transcritption following IL-6 treatment (and to a lesser extent following treatment with other cytokines) compared to controls. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0794b1f1-c2ef-45b3-b2f9-82fa11672605","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0794b1f1-c2ef-45b3-b2f9-82fa11672605_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22751495","allele":{"id":"https://genegraph.clinicalgenome.org/r/b6ea339c-e145-495c-b6df-a9621e9dd808","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.2137G>A (p.Val713Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399580186"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/0794b1f1-c2ef-45b3-b2f9-82fa11672605_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"patient B cells were transformed with EBV and treated with IL-6, IL-10, IL-21, or IFNa. Cells were assessed for pStat3 (pY705) by flow cytometry, stat3 nuclear translocation by EMSA ELISA, and mRNA levels of stat3-responsive gene (SOCS3) via RT-PCR following cytokine treatment. patient cells showed decreased phosphorylation, nuclear translocation, and induction of SOCS3 transcritption following IL-6 treatment (and to a lesser extent following treatment with other cytokines) compared to controls. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/3a71a6df-f5a4-46ab-bcb6-f3416159c537","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a71a6df-f5a4-46ab-bcb6-f3416159c537_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18602572","allele":{"id":"https://genegraph.clinicalgenome.org/r/7af6a8b8-7e70-4587-a0fc-aaa8c7e91479","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1907C>T (p.Ser636Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399582504"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/3a71a6df-f5a4-46ab-bcb6-f3416159c537_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reduction in TH17 CD4 T cells in peripheral blood of patient with this variant","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c11ff198-1d18-4e9a-a0df-0347f38fffdd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c11ff198-1d18-4e9a-a0df-0347f38fffdd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31346092","allele":{"id":"https://genegraph.clinicalgenome.org/r/2cbf8eb6-b0b6-475c-a9cc-1ee4e2c618b5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000017.11:g.42326288G>A (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2499553733"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/c11ff198-1d18-4e9a-a0df-0347f38fffdd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Luciferase based STAT3 functional assay in HEK293 (STAT3 sufficient cells) showing DN effect on variant","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f9a3f306-ce80-4f6a-9c27-408464c6f35e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f9a3f306-ce80-4f6a-9c27-408464c6f35e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22751495","allele":{"id":"https://genegraph.clinicalgenome.org/r/2125ac1d-a76f-43d7-9269-9e936213a000","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.2125A>G (p.Lys709Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399580215"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f9a3f306-ce80-4f6a-9c27-408464c6f35e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"patient B cells were transformed with EBV and treated with IL-6, IL-10, IL-21, or IFNa. Cells were assessed for pStat3 (pY705) by flow cytometry, stat3 nuclear translocation by EMSA ELISA, and mRNA levels of stat3-responsive gene (SOCS3) via RT-PCR following cytokine treatment. patient cells showed decreased phosphorylation, nuclear translocation, and induction of SOCS3 transcritption following IL-6 treatment (and to a lesser extent following treatment with other cytokines) compared to controls. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6de5355c-5b0f-4f46-91d5-10068caaa6e3","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6de5355c-5b0f-4f46-91d5-10068caaa6e3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18602572","allele":{"id":"https://genegraph.clinicalgenome.org/r/c87eaead-07f7-4281-a7d4-8a613e4f7323","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1909G>A (p.Val637Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341510"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/6de5355c-5b0f-4f46-91d5-10068caaa6e3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reduced TH17 CD4 T cells in PBMCs","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f8d0be48-b218-4bc5-89fc-60a2fb97f0fc","type":"EvidenceLine","dc:description":"This variant was scored 1.5 points as there were strong functional studies demonstrating STAT3 LOF when the variant was present.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f8d0be48-b218-4bc5-89fc-60a2fb97f0fc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17676033","allele":{"id":"https://genegraph.clinicalgenome.org/r/607343a3-095a-4ff0-bc07-41e1d453d60f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1145G>A (p.Arg382Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341506"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f8d0be48-b218-4bc5-89fc-60a2fb97f0fc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Showed that IL-6 and IL-10 is reduced in patient cells. Using EBV transformed cells showed that STAT3 DNA binding activity of patient samples was reduced compared to controls. Lastly, HeLa cells were transduced with WT STAT3 or patient variants and then silenced WT STAT3 using siRNA, finding this variant reduced STAT3 functionality.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/1f343171-1071-49e6-a5c6-417bac8cb9d8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1f343171-1071-49e6-a5c6-417bac8cb9d8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22751495","allele":{"id":"https://genegraph.clinicalgenome.org/r/62465dcc-519e-41ed-8c8c-28646249b208","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1840A>G (p.Ser614Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10588651"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/1f343171-1071-49e6-a5c6-417bac8cb9d8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"patient B cells were transformed with EBV and treated with IL-6, IL-10, IL-21, or IFNa. Cells were assessed for pStat3 (pY705) by flow cytometry, stat3 nuclear translocation by EMSA ELISA, and mRNA levels of stat3-responsive gene (SOCS3) via RT-PCR following cytokine treatment. patient cells showed decreased phosphorylation, nuclear translocation, and induction of SOCS3 transcritption following IL-6 treatment (and to a lesser extent following treatment with other cytokines) compared to controls. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/204bbc59-31f6-4fde-b426-7bad98d183ef","type":"EvidenceLine","dc:description":"This variant was scored 1.5 points as there were strong functional studies demonstrating STAT3 LOF when the variant was present.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/204bbc59-31f6-4fde-b426-7bad98d183ef_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17676033","allele":{"id":"https://genegraph.clinicalgenome.org/r/166e982d-e598-4fb4-b0ef-86382f6bfe71","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1309C>T (p.His437Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399587824"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/204bbc59-31f6-4fde-b426-7bad98d183ef_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Showed that IL-6 and IL-10 is reduced in patient cells. Using EBV transformed cells showed that STAT3 DNA binding activity of patient samples was reduced compared to controls. Lastly, HeLa cells were transduced with WT STAT3 or patient variants and then silenced WT STAT3 using siRNA, finding this variant reduced STAT3 functionality.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/3daa6698-c35b-4512-b262-c1daabe277af","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3daa6698-c35b-4512-b262-c1daabe277af_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18602572","allele":{"id":"https://genegraph.clinicalgenome.org/r/87da6889-46ab-4fd5-a192-fba361f2610a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1003C>T (p.Arg335Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA260531"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/3daa6698-c35b-4512-b262-c1daabe277af_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient TH17 CD4 T cells are reduced in PBMCs stimulated ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/beb3aa5b-240e-45d7-969a-9de3e5564457_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/beb3aa5b-240e-45d7-969a-9de3e5564457_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/36105ff4-6f99-4bd8-8945-504e4c1c5f19","type":"EvidenceLine","dc:description":"This is an extensive work that demonstrates the vast majority of STAT3 LOF variants are dominant negative and not loss of heterozygosity. I have upgraded the score due to the vast number of variants tested, as well as the quality of the data generated.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bc5efe94-b47b-4d0e-a0a4-cdcbac02d67a","type":"FunctionalAlteration","dc:description":"Transfection of variants into HEK293 cells resulted in the reduction of STAT3 DNA binding for the majority of variants. For those variants without decreased DNA binding, alternative splicing was investigated, and it was found that alternative transcripts or translation reinitiating were being generated that resulted in variants with dominant negative effects. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34137790","rdfs:label":"STAT3 DNA binding"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1b520462-d6ee-41e8-b570-b128a1089f89","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5164df78-9d48-422a-956b-805d8bbd8b8c","type":"FunctionalAlteration","dc:description":"Early B cell signaling was studied in healthy control and STAT3 LOF patients. Sorted memory B cell stimulated and followed by TRIFM showed reduced contact area in the synapse, reduced actin recruitment to the synapse and reduced phosphorylated signaling molecules to the area of contact of the B cells","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33045280","rdfs:label":"TIRFM of patient B cells"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/beb3aa5b-240e-45d7-969a-9de3e5564457_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d2681833-7784-4435-b3a2-8e072b290fcb","type":"EvidenceLine","dc:description":"This was a rescue in human derived cells, therefore I have updated the score to 1.5 points","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/682bd9d3-eb4a-4f40-9b68-a21c7f26995b","type":"Finding","dc:description":"Base repaired fibroblasts show increased pSTAT3 levels after stimulation with IL-6, increased STAT3 binding to DNA and increased expression of CCL2 mRNA after IL-6 stimulation compared to unprepared controls fibroblast. These alterations in STAT3 have been demonstrated in many individuals with AD-HIES","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33876960","rdfs:label":"Base repair with CRISPR","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityCellCultureRescueCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/a36a6e33-d2bf-44ac-b5ba-b3c00cbcefe9","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b00fc69-0ea5-404b-b63d-26e5959dc528","type":"Finding","dc:description":"After therapy patients IgE levels were normal, Th17 CD4 T cell frequency was normal and the IL-21 induced phosphorylation of STAT3 was normal","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25962528","rdfs:label":"HSCT","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityHumanRescueCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/2486451c-d6a7-4c64-b3f1-14a5de8d8572","type":"EvidenceLine","dc:description":"I decreased the score because this is a complete loss of STAT3 in B cells, not a dominant negative variant. Therefore, it is likely a similar mechanism of action (reduced STAT3), but it can not be concluded that a deletion of STAT3 is the same as a dominant negative variant.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0a902c7b-d1fb-4a58-9be5-ac81bc478b66","type":"Finding","dc:description":"These mice showed increased production of IgE and were more prone to allergy induced lung inflammation in an OVA/Alum immunization/IN challenge model","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31026806","rdfs:label":"CD19cre STAT3 fl","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/bce9d44b-378e-49ec-b1f2-652d629a70ed","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95d5ee62-68a3-48c5-91df-bf8da977143c","type":"Finding","dc:description":"HIES is defined by increased levels of IgE. In this model the mice developed high levels of IgE, copying what is seen in patients. The mice also show decreased TH17 immune responses and susceptibility to bacterial infections, similar to what is seen in patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24632714","rdfs:label":"Mouse model_mut-STAT3","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":10655,"specifiedBy":"GeneValidityCriteria8","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Fl3P_-HIES4","type":"GeneValidityProposition","disease":"obo:MONDO_0007818","gene":"hgnc:11364","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_beb3aa5b-240e-45d7-969a-9de3e5564457-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}